Google Play icon

Developing New Ways to Treat Macular Degeneration

Share
Posted March 25, 2013

Northwestern University scientists are part of a multi-institution interdisciplinary consortium that has been awarded a $6.2 million grant over five years from the National Eye Institute to develop new treatments for exudative age-related macular degeneration (AMD).

Exudative AMD is the leading cause of blindness among aging Americans, and the global rate of AMD is expected to double in the next decade due to an aging population. The severe vision loss from AMD is caused by the overgrowth of blood vessels between the outer membrane of the eye and the retina. New therapeutic approaches are needed to restore eye function lost to the disease.

Led by the University of Wisconsin School of Medicine and Public Health, the consortium includes investigators from Northwestern’s Center for Developmental Therapeutics, the Feinberg School of Medicine and the McCormick School of Engineering and Applied Science as well as the University of Nebraska Center for Drug Delivery and Nanomedicine.

Each team and its specialists bring different skills and techniques to the question of treatment of exudative AMD. The consortium will leverage the diverse scientific expertise to characterize and test novel therapies for exudative AMD in animal models using cutting-edge approaches that combine signal transduction and physiology, chemistry, nanoparticles and novel imaging technology.

Northwestern is expected to receive approximately $3.9 million in funding over the five-year grant period. Olga V. Volpert, associate professor of urology at Feinberg, is the Northwestern principal investigator. The award will be managed by the Center for Developmental Therapeutics (CDT) within the Chemistry of Life Processes Institute.

The Northwestern scientists will design and characterize peptides that mimic the function of natural inhibitors of the blood vessel growth (angiogenesis) that causes AMD.

Consortium investigators will screen these novel peptides for their ability to stop neovascularization in animal models of AMD. The goal of the program is to advance one or more new therapeutics to investigative drug status and a phase I clinical trial. Advancements could lead to future National Eye Institute funding of clinical studies.

Source: Northwestern University

Featured news from related categories:

Technology Org App
Google Play icon
85,582 science & technology articles

Most Popular Articles

  1. New treatment may reverse celiac disease (October 22, 2019)
  2. The World's Energy Storage Powerhouse (November 1, 2019)
  3. Universe is a Sphere and Not Flat After All According to a New Research (November 7, 2019)
  4. "Helical Engine" Proposed by NASA Engineer could Reach 99% the Speed of Light. But could it, really? (October 17, 2019)
  5. ‘Artificial leaf’ successfully produces clean gas (October 22, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email